Previous Page  36 / 52 Next Page
Information
Show Menu
Previous Page 36 / 52 Next Page
Page Background

Volume 8, Issue 4 (Suppl)

J Vet Sci Technol, an open access journal

ISSN: 2157-7579

Veterinary 2017

September 04-05, 2017

Page 65

Notes:

conference

series

.com

September 04-05, 2017 | Paris, France

7

th

International Veterinary Congress

Surong Hasi, J Vet Sci Technol 2017, 8:4(Suppl)

DOI: 10.4172/2157-7579-C1-024

Study on in vivo activities of CYP3A enzyme in Bactrian camel with specific probe drug

T

he aim of the research is to study the in vivo activities of Bactrian camels' CYP3A enzymes by investigating the

pharmacokinetic characteristics of CYP3A specific probe drug Midazolam in Bactrian camel, and the effect of Itraconazole

on the pharmacokinetic behavior of Midazolam was studied simultaneously. Firstly, five healthy adult Bactrian camels were

intramuscularly injected with the single dose of 0.1 mg/kg Midazolam, and then blood samples were collected from the jugular

vein at different time following the administration. Secondly, after 7 days drug clearance period, these five experimental

camels were injected intramuscularly with the single dose of 0.1 mg/kg Itraconazole for 4 consecutive days, and following 2

h of last injection, Bactrian camels were administered intramuscularly with the single dose of 0.1 mg/kg Midazolam again.

Blood samples were collected by same route and same intervals as previous, and the plasma was separated by centrifugation.

The plasma concentration of Midazolam was determined high performance liquid chromatography-UV detection, and

the pharmacokinetic parameters of Midazolam were analyzed by WinNonLin 7.0 with non-compartmental model. The

pharmacokinetic parameters of Midazolam in group probe drug only and in group enzyme inhibitor plus probe drug were

as follows: the T

1/2

was 2.5±0.073 h and 3.674±0.29 h, T

max

was 0.85±0.09 h and 0.54±0.06 h, C

max

was 0.62±0.12 µg/mL and

0.80±0.06 µg/mL, AUC

0-t

was 1.47±0.35 h•µg/mL and 2.15±0.15 h•µg/mL, V

d

was 259.17±41.29 mL/kg and 152.09±22.49 mL/

kg, CL was 53.46±14.25mL/h/kg and 34.3±5.13mL/h/kg, andMRTwas 3.71±0.16 h and 4.60±0.52 h, respectively.Therefore, all

the T

1/2

, T

max

, C

max

and MRT of Midazolam in Bactrian camels were relatively low which indicated that Bactrian camels' CYP3A

enzyme possess high activity on metabolism of Midazolam. Furthermore, the CYP3A enzyme was significantly inhibited by

Itraconazole which can increase the T

1/2

, C

max

, AUC and MRT, and can reduce the T

max

of Midazolam in Bactrian camel.

Biography

Surong Hasi is currently working as a professor in college of veterinary medicine, inner mongolia agricultural university, and is a director of camel protection association of

Inner Mongolia. His research interests are mainly focused on the pharmacokinetic characteristics of veterinary drugs in different species, drug-drug interactions in animals,

pharmacological activities of camel milk and Bactrian camel CYP enzymes.

baohaas@163.com

Surong Hasi

Inner Mongolia Agricultural University, China